title: Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles.
abstract: The purpose of this study was to assess the effect of various formulation parameters on anti-CD205 antibody decorated poly(d, l-lactide co-glycolide) (PLGA) nanoparticles (NPs) in terms of their ability to target dendritic cells (DCs). In brief, emulsification solvent evaporation technique was adapted to design NP formulations using two different viscosity grades (low and high) of both ester and carboxylic acid terminated PLGA. Incorporation of ligand was achieved following physical adsorption or chemical conjugation processes. The physicochemical characterizations of formulations were executed to assess the effects of different solvents (chloroform and ethyl acetate), stabilizer percentage, polymer types, polymer viscosities, ligand-NP bonding types, cross-linkers, and cryoprotectants (sucrose and trehalose). Modification of any of these parameters shows significant improvement of physicochemical properties of NPs. Ethyl acetate was the solvent of choice for the formulations to ensure better emulsion formation. Infrared spectroscopy confirmed the presence of anti-CD205 antibody in the NP formulation. Finally, cytotoxicity assay confirmed the safety profile of the NPs for DCs. Thus, ligand modified structurally concealed PLGA NPs is a promising delivery tool for targeting DCs in vivo.
authors.affiliation: Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
authors.forename: Sheikh Tasnim
authors.initials: ST
authors.lastname: Jahan
authors.affiliation: Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
authors.forename: Azita
authors.initials: A
authors.lastname: Haddadi
mesh_terms: D015703:Antigens, CD / Q000378:metabolism*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003432:Cross-Linking Reagents / Q000494:pharmacology; D003451:Cryoprotective Agents / Q000494:pharmacology; D003713:Dendritic Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D037181:Lectins, C-Type / Q000378:metabolism*; D008024:Ligands; D015778:Minor Histocompatibility Antigens; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011956:Receptors, Cell Surface / Q000378:metabolism*; D012997:Solvents; D017550:Spectroscopy, Fourier Transform Infrared; D055672:Static Electricity; D014783:Viscosity
chemical_list: D015703:Antigens, CD; D003432:Cross-Linking Reagents; D003451:Cryoprotective Agents; C093569:DEC-205 receptor; D037181:Lectins, C-Type; D008024:Ligands; D015778:Minor Histocompatibility Antigens; D011956:Receptors, Cell Surface; D012997:Solvents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid
keywords: PLGA; anti-CD205; dendritic cells; nanoparticle